The use of cannabidiol (CBD) in pain reduction and opioid use after shoulder arthroscopy: A Double-Blind Randomized Control Study

Brief description of study

The purpose of this study is to see if cannabidiol (CBD) orally dissolving tablets (ODTs) following shoulder arthroscopic surgery can lessen post- surgical pain and/or lessen the amount of stronger pain medication (narcotics) needed following surgery. CBD comes from the cannabis plant and is non-psychoactive (i.e. does not produce a ‘high’ or altered mental state) as compared to tetrahydrocannabinol (THC), another compound found in cannabis. Researchers are studying different forms of CBD for potential use in treating pain, inflammation, and illnesses. One form of CBD is Food and Drug Administration (FDA) approved for treating severe types of epilepsy that affect children. In this study, the CBD ODT is considered an investigational drug because it is not Food and Drug Administration (FDA) approved for post-surgical pain.


Clinical Study Identifier: s19-01293
ClinicalTrials.gov Identifier: NCT04672252
Principal Investigator: Michael J Alaia.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.